Cathepsin B degradable star-shaped peptidic macromolecules for delivery of 2-methoxyestradiol

Molecular Pharmaceutics

Volumn 10, Issue 10, 2013, Pages 3776-3788

  Shankar, Ravi ^a,b   Samykutty, Abhilash ^a   Riggin, Corinne ^b   Kannan, Sneha ^b   Wenzel, Ursula ^a   Kolhatkar, Rohit ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

2 methoxyestradiol; Cathepsin B; Degradable polymer; Peptidic dendrimer

Indexed keywords

2 METHOXYESTRADIOL; AMINE TERMINATED STAR SHAPED PEPTIDIC MACROMOLECULE; BUFFER; CARBOXYL TERMINATED STAR SHAPED PEPTIDIC MACROMOLECULE; CATHEPSIN B; DENDRIMER; DRUG VEHICLE; TETRAPEPTIDE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MACROMOLECULE; MOLECULAR WEIGHT; PRIORITY JOURNAL;

CATHEPSIN B; CELL LINE, TUMOR; CELL SURVIVAL; DENDRIMERS; DRUG STABILITY; ESTRADIOL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; POLYMERS;

EID: 84888384634     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400261h     Document Type: Article

References (56)

1. Verenich, S.; Gerk, P. M. Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mol. Pharmaceutics 2010, 7, 2030-9.
2. Sutherland, T. E.; Anderson, R. L.; Hughes, R. A.; Altmann, E.; Schuliga, M.; Ziogas, J.; et al. 2-Methoxyestradiol-A unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents. Drug Discovery Today 2007, 12, 577-84.
3. Klauber, N.; Parangi, S.; Flynn, E.; Hamel, E.; D'Amato, R. J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997, 57, 81-6.
4. Fotsis, T.; Zhang, Y.; Pepper, M. S.; Adlercreutz, H.; Montesano, R.; Nawroth, P. P.; et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994, 368, 237-9.
5. Mueck, A. O.; Seeger, H. 2-Methoxyestradiol-biology and mechanism of action. Steroids 2010, 75, 625-31.
6. Dahut, W. L.; Lakhani, N. J.; Gulley, J. L.; Arlen, P. M.; Kohn, E. C.; Kotz, H.; et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol. Ther. 2006, 5, 22-7.
7. James, J.; Murry, D. J.; Treston, A. M.; Storniolo, A. M.; Sledge, G. W.; Sidor, C.; et al. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest. New Drugs 2007, 25, 41-8.
8. Kopecek, J. Polymer-drug conjugates: Origins, progress to date and future directions. Adv. Drug Delivery Rev. 2013, 65, 49-59.
9. Zhou, Y.; Kopecek, J. Biological rationale for the design of polymeric anti-cancer nanomedicines. J. Drug Targeting 2013, 21, 1. 26.
10. Duncan, R.; Vicent, M. J. Polymer therapeutics-prospects for 21st century: The end of the beginning. Adv. Drug Delivery Rev. 2013, 65, 60-70.
11. Allen, T. M.; Cullis, P. R. Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Delivery Rev. 2013, 65, 36-48.
12. Koshkaryev, A.; Sawant, R.; Deshpande, M.; Torchilin, V. Immunoconjugates and long circulating systems: Origins, current state of the art and future directions. Adv. Drug Delivery Rev. 2013, 65, 24. 35.
13. Kim, C. S.; Tonga, G. Y.; Solfiell, D.; Rotello, V. M. Inorganic nanosystems for therapeutic delivery: Status and prospects. Adv. Drug Delivery Rev. 2013, 65, 93-9.
14. Hoffman, A. S. Stimuli-responsive polymers: Biomedical applications and challenges for clinical translation. Adv. Drug Delivery Rev. 2013, 65, 10-6.
15. Felber, A. E.; Dufresne, M. H.; Leroux, J. C. pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. Adv. Drug Delivery Rev. 2012, 64, 979-92.
16. Graf, N.; Lippard, S. J. Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv. Drug Delivery Rev. 2012, 64, 993. 1004.
17. de la Rica, R.; Aili, D.; Stevens, M. M. Enzyme-responsive nanoparticles for drug release and diagnostics. Adv. Drug Delivery Rev. 2012, 64, 967-78.
18. Gondi, C. S.; Rao, J. S. Cathepsin B as a cancer target. Expert Opin. Ther. Targets 2013, 17, 281-91.
19. Roshy, S.; Sloane, B. F.; Moin, K. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev. 2003, 22, 271-86.
20. Mohamed, M. M.; Sloane, B. F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6, 764-75.
21. Reiser, J.; Adair, B.; Reinheckel, T. Specialized roles for cysteine cathepsins in health and disease. J. Clin. Invest. 2010, 120, 3421-31.
22. Duncan, R.; Vicent, M. J. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv. Drug Delivery Rev. 2010, 62, 272-82.
23. Vasey, P. A.; Kaye, S. B.; Morrison, R.; Twelves, C.; Wilson, P.; Duncan, R.; et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 1999, 5, 83-94.
24. Seymour, L. W.; Ferry, D. R.; Kerr, D. J.; Rea, D.; Whitlock, M.; Poyner, R.; et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 2009, 34, 1629-36.
25. Duncan, R. Polymer therapeutics as nanomedicines: new perspectives. Curr. Opin. Biotechnol. 2011, 22, 492-501.
26. Webster, R.; Elliott, V.; Park, B. K.; Walker, D.; Hankin, M., Taupin, P. PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. In PEGylated Protein Drugs: Basic Science and Clinical Applications; Veronese, F. M., Ed.; Birkhäuser: Basel; 2009; pp 127-46.
27. Park, K. The optimal formulation variables for tumor targeting. J. Controlled Release 2012, 157, 315-6.
28. Rao, P. N.; Cessac, J. W. A new, practical synthesis of 2-methoxyestradiols. Steroids 2002, 67, 1065-70.
29. Ho, A.; Kim, Y. E.; Lee, H.; Cyrus, K.; Baek, S. H.; Kim, K. B. SAR studies of 2-methoxyestradiol and development of its analogs as probes of anti-tumor mechanisms. Bioorg. Med. Chem. Lett. 2006, 16, 3383-7.
30. Pechar, M.; Ulbrich, K.; Subr, V.; Seymour, L. W.; Schacht, E. H. Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin. Bioconjugate Chem. 2000, 11, 131-9.
31. Borgman, M. P.; Ray, A.; Kolhatkar, R. B.; Sausville, E. A.; Burger, A. M.; Ghandehari, H. Targetable HPMA Copolymer-Aminohexylgeldanamycin Conjugates for Prostate Cancer Therapy. Pharm. Res. 2009, 26, 1407-18.
32. Kasuya, Y.; Lu, Z. R.; Kopeckova, P.; Tabibi, S. E.; Kopecek, J. Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates. Pharm. Res. 2002, 19, 115-23.
33. Wang, D.; Kopeckova, J. P.; Minko, T.; Nanayakkara, V.; Kopecek, J. Synthesis of starlike N-(2-hydroxypropyl)methacrylamide copolymers: potential drug carriers. Biomacromolecules 2000, 1, 313-9.
34. Kolhatkar, R. B.; Kitchens, K. M.; Swaan, P. W.; Ghandehari, H. Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjugate Chem. 2007, 18, 2054-60.
35. Fischer, D.; Li, Y.; Ahlemeyer, B.; Krieglstein, J.; Kissel, T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003, 24, 1121-31.
36. Ryser, H. J. A membrane effect of basic polymers dependent on molecular size. Nature 1967, 215, 934-6.
37. Seymour, L. W.; Ferry, D. R.; Anderson, D.; Hesslewood, S.; Julyan, P. J.; Poyner, R.; et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 2002, 20, 1668-76.
38. Pan, H.; Sima, M.; Yang, J.; Kopecek, J. Synthesis of Long-Circulating, Backbone Degradable HPMA Copolymer-Doxorubicin Conjugates and Evaluation of Molecular-Weight-Dependent Antitumor Efficacy. Macromol. Biosci. 2013, 13, 155-60.
39. Shiah, J. G.; Dvorak, M.; Kopeckova, P.; Sun, Y.; Peterson, C. M.; Kopecek, J. Biodistribution and antitumour efficacy of longcirculating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice. Eur. J. Cancer 2001, 37, 131-9.
40. Dvorak, M.; Kopeckova, P.; Kopecek, J. High-molecular weight HPMA copolymer-adriamycin conjugates. J. Controlled Release 1999, 60, 321-32.
41. Rejmanova, P.; Kopecek, J.; Duncan, R.; Lloyd, J. B. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers. Biomaterials 1985, 6, 45-8.
42. Etrych, T.; Chytil, P.; Jelinkova, M.; Rihova, B.; Ulbrich, K. Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage. Effect of spacer on drug release and in vitro cytotoxicity. Macromol. Biosci. 2002, 2, 43-52.
43. Caiolfa, V. R.; Zamai, M.; Fiorino, A.; Frigerio, E.; Pellizzoni, C.; d'Argy, R.; et al. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J. Controlled Release 2000, 65, 105-19.
44. Duncan, R.; Kopeckova-Rejmanova, P.; Strohalm, J.; Hume, I.; Cable, H. C.; Pohl, J.; et al. Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro. Br. J. Cancer 1987, 55, 165-74.
45. Kopecek, J.; Rejmanova, P.; Duncan, R.; Lloyd, J. B. Controlled release of drug model from N-(2-hydroxypropyl)-methacrylamide copolymers. Ann. N.Y. Acad. Sci. 1985, 446, 93-104.
46. Rejmanova, P.; Kopecek, J.; Pohl, J.; Baudys, M.; Kostka, V. Polymers Containing Enzymatically Degradable Bonds 0-8. Degradation of Oligopeptide Sequences in N-(2-Hydroxypropyl)-Methacrylamide Co-Polymers by Bovine Spleen Cathepsin-B. Makromol. Chem. 1983, 184, 2009-20.
47. Khouri, H. E.; Plouffe, C.; Hasnain, S.; Hirama, T.; Storer, A. C.; Menard, R. A model to explain the pH-dependent specificity of cathepsin B-catalysed hydrolyses. Biochem. J. 1991, 275 (Part 3), 751-7.
48. Nagler, D. K.; Storer, A. C.; Portaro, F. C.; Carmona, E.; Juliano, L.; Menard, R. Major increase in endopeptidase activity of human cathepsin B upon removal of occluding loop contacts. Biochemistry 1997, 36, 12608-15.
49. Musil, D.; Zucic, D.; Turk, D.; Engh, R. A.; Mayr, I.; Huber, R.; et al. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J. 1991, 10, 2321-30.
50. Illy, C.; Quraishi, O.; Wang, J.; Purisima, E.; Vernet, T.; Mort, J. S. Role of the occluding loop in cathepsin B activity. J. Biol. Chem. 1997, 272, 1197-202.
51. Renko, M.; Pozgan, U.; Majera, D.; Turk, D. Stefin A displaces the occluding loop of cathepsin B only by as much as required to bind to the active site cleft. FEBS J. 2010, 277, 4338-45.
52. Ruzza, P.; Quintieri, L.; Osler, A.; Calderan, A.; Biondi, B.; Floreani, M.; et al. Fluorescent, internally quenched, peptides for exploring the pH-dependent substrate specificity of cathepsin B. J. Pept. Sci. 2006, 12, 455-61.
53. Krupa, J. C.; Hasnain, S.; Nagler, D. K.; Menard, R.; Mort, J. S. S2' substrate specificity and the role of His110 and His111 in the exopeptidase activity of human cathepsin B. Biochem. J. 2002, 361, 613-9.
54. Quraishi, O.; Nagler, D. K.; Fox, T.; Sivaraman, J.; Cygler, M.; Mort, J. S.; et al. The occluding loop in cathepsin B defines the pH dependence of inhibition by its propeptide. Biochemistry 1999, 38, 5017-23.
55. Xing, R.; Addington, A. K.; Mason, R. W. Quantification of cathepsins B and L in cells. Biochem. J. 1998, 332 (Part 2), 499-505.
56. Cho, J. K.; Hong, K. Y.; Park, J. W.; Yang, H. K.; Song, S. C. Injectable delivery system of 2-methoxyestradiol for breast cancer the rapy using biodegradable thermosensitive poly-(organophosphazene) hydrogel. J. Drug Targeting 2011, 19, 270-80.